title: Who should receive myeloablative therapy for lymphoma?
authors.affiliation: Department of Medical Oncology, St. Bartholomew's Hospital, London.
authors.forename: T Andrew
authors.initials: TA
authors.lastname: Lister
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008223:Lymphoma / Q000628:therapy*; D011241:Prednisone / Q000008:administration & dosage; D033581:Stem Cell Transplantation; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone